CONNEQT Health Delivers Strong December Quarter Sales Momentum.
CONNEQT Health Limited (ASX: CQT) has reported a robust sales update for the December 2025 quarter, with demand for its CONNEQT Pulse arterial health monitor exceeding internal expectations. Building on strong momentum from FY25, quarterly revenue and unit sales are tracking ahead of the 200% quarter-on-quarter growth guidance outlined at the November Annual General Meeting. The period was highlighted by multiple record daily sales results and a material uplift in volumes over the Black Friday promotional window. Importantly, customer acquisition and advertising costs came in below forecasts, reflecting improved marketing efficiency and higher conversion rates. Early adoption of the Care+ subscription offering through the CONNEQT app also gained traction, supporting the Company’s strategy to develop recurring, subscription-based revenue streams. Management expects positive sales momentum to continue into the March quarter, underpinned by expanded marketing activity, seasonal demand tailwinds and growing brand awareness in the U.S. consumer health market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
CONNEQT Health Delivers Strong December Quarter Sales Momentum.
CONNEQT Health Limited (ASX: CQT) has reported a robust sales update for the December 2025 quarter, with demand for its CONNEQT Pulse arterial health monitor exceeding internal expectations. Building on strong momentum from FY25, quarterly revenue and unit sales are tracking ahead of the 200% quarter-on-quarter growth guidance outlined at the November Annual General Meeting. The period was highlighted by multiple record daily sales results and a material uplift in volumes over the Black Friday promotional window. Importantly, customer acquisition and advertising costs came in below forecasts, reflecting improved marketing efficiency and higher conversion rates. Early adoption of the Care+ subscription offering through the CONNEQT app also gained traction, supporting the Company’s strategy to develop recurring, subscription-based revenue streams. Management expects positive sales momentum to continue into the March quarter, underpinned by expanded marketing activity, seasonal demand tailwinds and growing brand awareness in the U.S. consumer health market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au